Anika Therapeutics Inc.

ANIK Healthcare Drug Manufacturers Specialty & Generic

Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

19.98 0.71 −3.43%
Market cap
$276.9M
P/E
0.0×
Fwd P/E
−20.0×
Dividend yield
—
F-score
6/9
Altman Z
3.13
Beneish M
−2.84
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 6 6 6

+8 more TTM periods

ROE
(2.66%) (7.84%) (7.32%) (20.23%)
ROA
(2.04%) (5.98%) (5.54%) (15.70%)
ROIC
(3.24%) (8.25%) (8.03%) (8.73%)
Return on Tangible Assets
(3.23%) (9.85%) (8.93%) (26.82%)
Average Days of Receivables
87.92 80.90 76.64 71.79
Free Cash Flow per Share
0.04 (0.21) 0.35 0.09
Free Cash Flow
0.56 (2.86) 4.96 1.25
Capital Expenditures
(5.41) (9.33) (6.23) (6.88)
Other line items
Cash ROIC
0.32% (1.63%) 2.47% 0.61%
Accounts Receivable Turnover
4.55 4.87 4.77 4.46
Accounts Payable Turnover
8.29 8.29 8.41 8.85
Inventory Turnover
2.01 2.18 2.30 1.83
Average Days of Payables
49.86 48.06 44.99 33.83
Days of Inventory on Hand
228.39 173.16 139.91 116.42
Tax Rate
0.07 0.08 0.07 0.42
Research and Development Expense of Revenue
22.75% 22.73% 22.84% 22.89%
Selling, General and Administrative Expense of Revenue
43.66% 46.41% 43.51% 42.84%
Share Based Compensation of Revenue
10.90% 11.92% 8.94% 8.76%
Operating CF/Net income
(1.58) (0.58) (1.03) (0.25)
Depreciation/Fixed assets
0.14 0.14 0.14 0.14
Capex/Depreciation
(0.96) (1.68) (1.09) (1.23)
Revenue per Share
9.05 8.59 7.87 7.82
Operating CF per Share
0.45 0.48 0.78 0.56
Capex per Share
(0.41) (0.69) (0.43) (0.48)
Capex to Sales
0.04 0.08 0.06 0.06

Fold the line items

Columns are period end dates